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Matriptase Regulates Proliferation and Early, but Not
Terminal, Differentiation of Human Keratinocytes
Ya-Wen Chen1,2, Jehng-Kang Wang3, Fen-Pai Chou1, Bai-Yao Wu4, Hui-Chung Hsiao3, Han Chiu3,
Zhonghong Xu1, Adrienne N.H. Baksh5, Galen Shi6, Malvika Kaul7, Robert Barndt8,
Victoria K. Shanmugam9, Michael D. Johnson8 and Chen-Yong Lin8
Genetic defects in matriptase are linked to two congenital ichthyoses: autosomal recessive ichthyosis with
hypotrichosis (ARIH, OMIM 610765) and ichthyosis, follicular atrophoderma, hypotrichosis, and hypohidrosis
(IFAH, OMIM 602400). Mouse models with matriptase deficiency indicate an involvement of matriptase in
suprabasal keratinocytes in the maintenance of the epidermal barrier. In contrast to what has been reported for
mouse skin, we show that in human skin matriptase is primarily expressed in the basal and spinous keratinocytes,
but not in the more differentiated keratinocytes of the granular layer. In addition, matriptase zymogen activation
was predominantly detected in the basal cells. Furthermore, by using skin organotypic cultures as a model system
to monitor the course of human epidermal differentiation, we found elevated matriptase zymogen activation
during early stages of epidermal differentiation, coupled with a loss of matriptase expression in the late stages of
this process. We also show here that matriptase deficiency in HaCaT cells modestly reduces cell proliferation and
temporally affects calcium-induced expression of differentiation markers. These collective data suggest that,
unlike mouse matriptase, human matriptase may be involved in the regulation of keratinocyte growth and early
differentiation, rather than terminal differentiation, providing mechanistic insights into the pathology of the two
congenital ichthyoses: ARIH and IFAH.
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INTRODUCTION
The genetic skin disorders autosomal recessive ichthyosis with
hypotrichosis (ARIH) and ichthyosis, follicular atrophoderma,
hypotrichosis, and hypohidrosis (IFAH) have been recently
shown to be associated with mutations in matriptase, a type
2 integral membrane serine protease (Basel-Vanagaite et al.,
2007; Avrahami et al., 2008; Alef et al., 2009). Defects in
skin barrier function represent the underlying pathogenic
mechanisms for patients with these disorders, as observed
in a majority of other congenital ichthyoses (Akiyama and
Shimizu, 2008). Such defects in skin barrier function for
ichthyosis pathogenesis result from impairments in at least
one of the three major components of the stratum corneum (SC)
barrier: (1) intercellular lipid layers, (2) cornified cell envelop,
and (3) keratin/profilaggrin degradation products (Akiyama and
Shimizu, 2008). Disruptions in profilaggrin processing appear
to be the principal contributor to the impaired skin barrier
observed in patients with matriptase mutations (Alef et al.,
2009). Histological and ultrastructural analyses of the skin
of ARIH patients further reveals that impaired degradation
of corneodesmosomes and thickened stratum spinosum
(acanthosis), as well as thickened SC, are associated with this
condition (Basel-Vanagaite et al., 2007). Degradation of both
corneodesmosomes and profilaggrin requires intensive
proteolysis. It is tempting to speculate that matriptase may
be involved in these proteolytic processes, but its role, direct
or indirect, in either corneodesmosomes or profilaggrin
degradation has yet to be elucidated. The acanthosis and the
thickened SC associated with matriptase mutations could result
from the impact of the mutation on keratinocyte proliferation
and differentiation that is propagated through multiple
downstream steps rather than just the result of one specific
proteolytic event. Therefore, matriptase may indirectly regulate
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multiple processes in skin from the formation of the SC barrier
to the maintenance of epidermal homeostasis through the
desquamation and/or the replenishment of keratinocytes.
Animal model systems with targeted deletion of matriptase
have been generated and provided insights into the role of
matriptase in skin barrier formation and its dysregulation in
ichthyosis. In addition to replicating the ichthyotic phenotype
and impaired profilaggrin processing seen in the ARIH and
IFAH patients, impaired tight-junction activity has also been
identified to have an important role in the loss of epidermal
barrier function in the skin of matriptase knockout mice
(List et al., 2009). Significantly, experiments with matriptase
knockout mice further revealed that zymogen activation of
prostasin, a glycosylphosphatidylinositol-anchored serine
protease, was compromised in the mouse skin (Netzel-Arnett
et al., 2006). Given the almost identical epidermal defects
observed in both matriptase and prostasin knockout mice and
the colocalization of the two proteases in the outermost layer
of the viable keratinocytes, the lack of matriptase-mediated
zymogen activation of prostasin is likely to be responsible
for the epidermal defects in matriptase knockout mice.
Interestingly, the lack of prostasin zymogen activation was
also reported in the skin of the IFAH patients (Alef et al.,
2009). The functional link between the two membrane-bound
serine proteases was also demonstrated in immortalized
human keratinocytes in which prostasin zymogen activation
was shown to be dependent on matriptase (Chen et al.,
2010b). Zymogen activation of both serine proteases is
under extremely tight control of hepatocyte growth factor
activator inhibitor (HAI)-1, a Kunitz-type serine protease
inhibitor, in a manner such that HAI-1 binds to and inhibits
the serine proteases virtually at the same time that zymogen
activation of the proteases occurs (Chen et al., 2010b). It is
noteworthy that targeted deletion of HAI-1 in mice also
causes ichthyosis-like skin with aberrant profilaggrin pro-
cessing and acanthosis (Nagaike et al., 2008). The matriptase–
prosatssin–HAI-1 cell surface protease network, therefore,
appears to be an essential process for maintenance of skin
barrier function.
Matriptase knockout mice may appear to be an excellent
tool to study the physiological roles of matriptase in the skin
and to understand the development and progression of
human skin diseases, given the shared epidermal defects
associated with matriptase deficiency, the propagation
through the same downstream substrate, prostasin, and the
control by the same antiprotease mechanism, HAI-1, between
humans and rodents. This is particularly true for the matrip-
tase hypomorphic mice, which phenocopy ARIH patients (List
et al., 2007). However, the less-severe non-life-threatening
clinical presentation of IFAH patients with deletion of
matriptase when compared with the uniform death within
48 hours after birth due to impaired skin barrier function
observed in matriptase knockout mice indicates that there are
important differences in matriptase functions between
humans and mice (List et al., 2002). Therefore, there is a
need to establish human relevant models to understand the
role of matriptase in the ARIH and IFAH. To this end, we
investigated the distribution profiles of matriptase expression
in human skin, as well as in an in vitro skin organotypic
culture model, in which the dynamic processes of robust
epidermal differentiation and tissue regeneration can be
tracked. The state of matriptase zymogen activation was
also probed for using a unique matriptase mAb that can
distinguish between activated matriptase from matriptase
zymogen. In addition, HaCaT human keratinocytes were
used to investigate the effects of MTP KD. Regarded as a
whole, our data suggest that human matriptase is likely to be
involved in the regulation of proliferation and early diffe-
rentiation primarily in basal keratinocytes. This conclusion is
in a stark contrast to the role played by mouse matriptase,
which is expressed by suprabasal but not basal keratinocytes,
with highest expression observed in the outermost viable
keratinocytes, indicating involvement in late stages of kerati-
nocyte differentiation.
RESULTS
Distribution and zymogen activation of matriptase in human skin
We analyzed the distribution profiles of matriptase by immu-
nohistochemistry. The specificity of the matriptase mAbs used
in this study has been established in multiple previous
publications by immunoblot analysis and fluorescent immu-
nocytochemical staining (Benaud et al., 2001, 2002; Hung
et al., 2004; Wang et al., 2009; Tseng et al., 2010; Chen et al.,
2010b). To cross-validate the pattern of matriptase staining
observed in this study, however, we conducted staining for
matriptase on sections of the same sample of human neonatal
foreskin using two independent anti-matriptase mAbs: M32
and M24 (Figure 1a and b). We also stained skin sections from
a human–mouse xenograft model that contained both human
and mouse epidermis (Figure 1c and d). We conducted these
additional studies because of the stark contrast between the
matriptase expression pattern we find in human skin and what
has been reported in rodent skin (Netzel-Arnett et al., 2006).
These findings are also at odds with two previous reports of
the distribution of matriptase in human skin discussed below
(Mildner et al., 2006; Bocheva et al., 2009)
Additional human skin sections in which the basal layer,
stratum basale (SB), spinous layer, stratum spinosum (SS), and
granular layer, stratum granulosum (SG) can clearly be
discriminated were stained for matriptase (Figure 2a). Matrip-
tase was detected at cell–cell junctions in the SB and SS
(Figure 2b). However, decreasing expression of matriptase was
observed along with the progression of differentiation from the
SS to the SG. The expression of matriptase becomes unde-
tectable in SG keratinocytes with dense cytoplasm that border
the cornified layer (SC), which is the outermost layer and is
also matriptase negative (Figure 2b). These data suggest that
matriptase expression might be differentiation regulated, and
that the physiological function of matriptase in skin likely lies
in the earlier stages of differentiation (SB and SS layers) rather
than the later stage of differentiation (SG layer). In addition to
the samples of neonatal foreskin, human skin xenograft, and
samples of non-affected skin from patients with skin disease
studied, the distribution profile of matriptase expression was
also observed in the skin specimens from the scalp of a
healthy adult (data not shown). These expression analyses
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suggest a consistent distribution profile for matriptase in
human epidermis regardless of the origins of skin samples.
Similar to the matriptase expression pattern, HAI-1 expres-
sion was also observed at the cell–cell junctions of the cells in
the SB and SS layers (Figure 2c). However, in contrast to the
lack of matriptase expression in the SG layer, high levels of
HAI-1 expression were observed in this layer. Moreover, the
HAI-1 present in the SG layer exhibited altered subcellular
localization compared with the other layers, being present
primarily in the cytoplasm rather than at the cell–cell junctions
(Figure 2c). The observed differential expression of matriptase
and HAI-1 at the SG layer points toward a functional
divergence of this cognate protease and protease inhibitor
pair in terminally differentiated human keratinocytes.
Next, we sought to examine the status of matriptase
zymogen activation in human skin. To this end, we compared
the staining patterns of 55 frozen sections of human skin using
either the total matriptase-specific mAb or the activated
matriptase-specific mAb (Figure 3). Although all 55 samples
were positive for total matriptase (100%), only 24 of the
H&E Total MTP HAI-1
SC
SG
SS
SB
Figure 2. Cellular localization of matriptase and HAI-1 in normal human skin. Frozen sections from normal human skin were stained with hematoxylin and eosin
(H&E, a) or immunostained with mAb M32 for total matriptase (total MTP, b), or mAb M19 for HAI-1 (c). Nuclei of cells in all three panels were counterstained
blue with hematoxylin. The epidermal layers are indicated by SB for the stratum basale, SS for the stratum spinosum, SG for the stratum granulosum, and SC for the
stratum corneum. HAI-1, hepatocyte growth factor activator inhibitor. Bar ¼ 25mm.
Mouse Human
Human Mouse
Figure 1. The specificity of matriptase mAbs in immunohistochemical staining. Paraffin-embedded tissue sections prepared from human neonatal foreskin and
human skin graft onto the nude mice. The foreskin sections (upper panels) immunostained with two monoclonal antibodies for total matriptase, M32 (a) and
M24 (b). The human skin graft immunostained with M32 (c and d). Nuclei of cells were counterstained blue with hematoxylin. Bar ¼ 50mm.
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55 samples were positive for activated matriptase (44%). Two
representative positive sections for each mAb are shown
in Figure 3. Inspection of these sections reveals distinctly
different distribution patterns of activated matriptase in
comparison with total matriptase. Although the level of
positive staining for total matriptase in the basal cell layer
was similar to the corresponding level in the spinous cell
layer, positive staining for activated matriptase was observed
almost exclusively in the basal layer, with positive staining for
activated matriptase in spinous cells rarely being observed.
When present, the activated matriptase-positive spinous cells
were typically present as isolated individual cells or as cell
clusters next to basal cells. On the odd occasion, activated
matriptase-positive staining was observed in spinous cells
that were a couple of layers above the basal layer. At
high magnification (Figures 3c and f), activated matriptase
appeared as discontinuous bar-like bridges connecting two
neighboring cells. These collective observations suggest that
the basal keratinocyte layer is likely to be the primary location
in which matriptase actively exercises its physiological func-
tion in human epidermis.
Elevated matriptase activation at the early stages of epidermal
differentiation and loss of matriptase expression at the late stages
of epidermal differentiation
The expression and zymogen activation state of matriptase in
human skin revealed by our immunohistochemistry data thus
far suggested that matriptase may be more important in
the early stages of keratinocyte differentiation rather than
the later stages. To further examine this hypothesis, we
analyzed matriptase expression and zymogen activation
along the course of epidermal differentiation in organotypic
skin cultures using human primary keratinocytes isolated
from foreskin. This in vitro skin culture system closely
mimics epidermal regeneration and keratinocyte differen-
tiation in skin (Akgul et al., 2005; Chong et al., 2009;
Westphal et al., 2009).
Primary human keratinocytes maintained in low-Ca2þ
culture medium in a monolayer expressed the zymogen form
of matriptase, as can be seen in the immunoblot shown in
Figure 4a, lane M. In the organotypic cell culture system,
primary keratinocytes are induced to differentiate by growing
them on a fibroblast-primed collagen matrix plug in medium
containing high Ca2þ for 2 days and then lifting the plugs
such that the cells are grown at the collagen–air interface.
Keratinocytes that have been induced to undergo differentia-
tion in this manner exhibited high levels of activated matrip-
tase (Figure 4a, lanes R), in contrast to the uninduced primary
keratinocytes that only expressed matriptase zymogen
(Figure 4a, lane M). These results support the hypothesis that
matriptase zymogen activation occurs upon keratinocyte
differentiation.
To further explore matriptase and HAI-1 expression and
localization patterns during epidermal differentiation, primary
Total MTP Activated MTP
Total Positive
24
43.6 56.4
31
Negative
55
100%
Cases
Activated MTP
Figure 3. Matriptase activation in the basal layer of the epidermis. Frozen sections of human skin from 55 specimens were immunostained with mAb M32 for
total matriptase (a, d, total MTP) or mAb M69 for activated matriptase (b, e, activated MTP). Higher magnification for the micrographs b and e are presented
as c and f, respectively. Nuclei were counterstained blue with hematoxylin. A negative control using mouse IgG was also performed (not shown). The table shows
the numbers and percentages of skin specimens with positive- and negative-activated matriptase. MTP, matriptase. Bar ¼ 25mm.
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keratinocytes that had been induced to undergo differentiation
in the organotypic cultures were analyzed by immunohisto-
chemistry on days 0, 3, 5, and 9 after lifting the cells to the
air–liquid interface (Figures 4b and c). Both matriptase and
HAI-1 were homogenously detected on the cell surface in
cells of all layers on day 0 when the keratinocytes were lifted
to the air (Figures 4b and c, day 0). These data suggest that the
keratinocytes that are undergoing early steps of differentiation
induced by Ca2þ and the collagen matrix still maintained the
serine protease system. However, by day 3, loss of matriptase
expression begins to occur at the outermost layer of keratino-
cytes, whose nuclei now appear to be slightly condensed and
elongated (Figure 4b, day 3). By day 5, when robust differ-
entiation was observed with the appearance of the keratino-
cytes either with condensed nuclei or without nuclei on the
upper layers, the expression of matriptase and HAI-1 was
confined to a couple of keratinocyte layers near the collagen
matrix (Figures 4b and c, day 5). By day 9, the skin raft
contained basal cells with altered orientation and thick
cornified layers, and expression of matriptase and HAI-1 was
again limited to the same couple of layers, as observed on
day 5. In summary, our results reveal that the expression of
matriptase and HAI-1 is differentiation dependent; they
are highly expressed in proliferating (in monolayer culture in
low-Ca2þ medium) and early differentiating keratinocytes, but
are lost during late stages of differentiation.
Role of matriptase in keratinocyte proliferation and
differentiation
We next used the human keratinocyte cell line HaCaT
in which matriptase expression was knocked down with
matriptase-targeting small hairpin RNA (shRNA) to further
explore the role of matriptase in keratinocyte proliferation and
early-stage differentiation. Figure 5a shows that matriptase
expression was significantly reduced in the pools expressing
the matriptase-targeting shRNA, whereas the non-target
shRNA-expressing pools exhibited robust matriptase expres-
sion. HAI-1 expression was not affected by the cellular
expression of either shRNA (Figure 5a). Figure 5b shows the
comparison of growth curves of matriptase-targeting (MTP KD)
and non-target (NT) control pools using the crystal violet
staining proliferation assay. Knockdown of matriptase expres-
sion in HaCaT cells resulted in a statistically significant
decrease in cellular proliferative ability by 37.5% (Po0.01)
in comparison with the non-target control cells (Figure 5b).
These data suggest that matriptase expression levels affect
human keratinocyte proliferation.
We further investigated the impact of MTP KD on kerati-
nocyte differentiation by using RT-PCR to determine the
mRNA levels of three differentiation markers: keratin 1 (K1),
keratin 10 (K10), and involucrin. For these studies, both MTP
KD and NT HaCaT pools were adapted to the basal cell-like
state by being maintained in low-calcium medium (Deyrieux
and Wilson, 2007). We were unable to detect K1 or K10
expression in the NT pools, which has been adapted in low-
Ca2þ medium, with the expression of these two proteins
being detected only when the cells were grown in high-Ca2þ
medium that induces differentiation (Figures 6c and d).
Growth of NT HaCaT cells in the high-Ca2þ medium also
increased the expression level of matriptase itself, as well as
involucrin (Figures 6a and e), while having minimal impact,
if any, on the expression level of HAI-1. These data are
consistent with the notion that high-Ca2þ media induce
differentiation in HaCaT cells.
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Figure 4. Matriptase and HAI-1 in an organotypic skin culture. (a) Expression and zymogen activation of matriptase. Primary human keratinocytes were grown in
monolayer (M) or in an organotypic skin culture system (R). Cells were harvested on the day before they were lifted to the air–liquid interface and analyzed
by immunoblotting for total matriptase (total MTP). The appearance of the 120-kDa matriptase complex with HAI-1 indicates the zymogen activation of matriptase.
(b, c) Expression of matriptase and HAI-1 over the course of epidermal differentiation. Organotypic skin cultures on days 0, 3, 5, and 9 after lifting them to the
air–liquid interface were analyzed by immunohistochemistry for total matriptase (total MTP) using mAb M24 and HAI-1 (HAI-1) using mAb M19. Nuclei were
counterstained blue with hematoxylin. HAI-1, hepatocyte growth factor activator inhibitor. Bar ¼ 20mm.
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After exposing the cells in high-calcium medium for 1 day,
the K1 and K10 expression levels were significantly lower in
the MTP KD HaCaT pools as compared with the NT control
pools (Figures 6c and d). Similarly, the 24-hour exposure to
high-Ca2þ medium failed to increase the expression level
of involucrin in the MTP KD pools (Figure 6e). As observed
Total MTP
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Figure 5. Role of matriptase (MTP) in keratinocyte proliferation. (a) Matriptase and HAI-1 expression in MTP knockdown (MTP KD) cells. The cell lysates of the
two MTP KD pools (49 and 52) and the NT control (NT) were analyzed by immunoblotting for matriptase (total MTP) or HAI-1 (HAI-1). (b) Decreased proliferation
in MTP KD cells. Growth curves of the MTP KD pools 52 (MTP knockdown) and the non-target control (non-target) were determined by the crystal violet staining
assay. Each point corresponds to the mean and standard error of experiments carried out in quadruplicate. The results presented are from one experiment
representative of the four performed. HAI-1, hepatocyte growth factor activator inhibitor.
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Figure 6. Role of matriptase in keratinocyte differentiation. The mRNA levels of matriptase, HAI-1, K1, K10, and involucrin were analyzed by real-time PCR in
MTP KD pools 52 (MTP KD) and the non-target control (NT). The cells were grown either in low-Ca2þ or high-Ca2þ medium for 24 hours (a–e), as indicated. In
panels f, g, and h, the cells were grown in low Ca2þ for 1 day or 5 days, as indicated. The fold changes of mRNA levels were quantified by normalization relative to
the controls indicated. Mean values±SD (n¼ 4) are plotted. The results presented are from one experiment representative of the four performed. HAI-1, hepatocyte
growth factor activator inhibitor; mRNA, messenger RNA; MTP, matriptase; MTP KD, MTP knockdown.
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for the NT HaCaT pools, higher matriptase expression was
observed in MTP KD clones grown in high-Ca2þ medium
compared with low-Ca2þ medium (Figure 6a), whereas the
expression of HAI-1 was not affected by the calcium con-
centration of the growth medium (Figure 6b). The impact of
MTP KD on the calcium-induced expression of the three
differentiation markers seems to be a temporal event, as the
expression of the differentiation markers is highly dependent
on cell density regardless of the presence of calcium. At high
confluence, E-cadherin adherens junctions are formed (data
not shown) and the expression of these differentiation makers
increase to high levels. This phenomenon can be seen not
only for the NT cells but also for MTP KD cells (Figures 6f, g,
and h). These data suggest that matriptase might affect
keratinocyte differentiation by transiently reducing the expres-
sion of the differentiation markers. The transient nature of this
effect on the expression of K1, K10, and involucrin in our
culture cell model is consistent with the observation that the
expression of these markers is not altered in ARIH patients,
where the delay in differentiation would be difficult to detect
(Basel-Vanagaite et al., 2007).
DISCUSSION
Genotypic studies of patients with the hereditary disorders
ARIH and IFAH have revealed the importance of matriptase in
human skin. The results described in this paper provided
mechanistic insights into matriptase function in human kera-
tinocytes, which has implications on how matriptase dysre-
gulation could affect skin ichthyosis observed in these genetic
disorders. We find that matriptase is highly expressed by the
keratinocytes in the basal and spinous layers of the epidermis,
but not in the granular layer. In vitro organotypic skin rafts
recapitulate the differentiation-dependent distribution profile
of matriptase expression. We also present evidence that
matriptase zymogen activation is maximal in the basal layer
of skin. Our collective results suggest that the mutations
associated with matriptase in ARIH and IFAH would likely
affect biological functions of basal keratinocytes the most,
which then leads to ichthyosis.
The basal layer contains three subpopulations of keratino-
cytes: 1) stem cells, 2) transit-amplifying cells, and 3) post-
mitotic differentiating cells (Wheater et al., 1993; Ross et al.,
1995). The major function of the basal keratinocytes is to
maintain the stem cell population through mitosis and to
replenish the cells in the epidermis through differentiation.
Once differentiation is initiated, keratinocytes move toward
the spinous layer and continue to differentiate from one layer
to the next until they reach the final layer, the SC (Eckert,
1989; Lindsay, 1996). Given that we observed homogenous
matriptase expression in the entire basal layer, and that its
zymogen activation, when present, was also associated with
the entire basal layer, we propose that matriptase participates
in a shared program among the subpopulations of basal
keratinocytes. In other words, our studies are consistent with
the hypothesis that matriptase is involved in the growth
regulation and early differentiation of basal keratinocytes.
This hypothesis is supported by our functional analysis
using MTP KD cells. Keratinocytes in which matriptase has
been knocked down grow more slowly and transiently
express lower levels of the three differentiation markers K1,
K10, and involucrin in response to the differentiation
agent Ca2þ .
Our results indicate that matriptase likely has a very limited
role in epidermal terminal differentiation owing to its dimin-
ishing expression along the progression of differentiating
keratinocytes from the SS to the SG. Given this limited role
in granular keratinocytes, it implies that matriptase is less
likely to participate in the formation of skin barrier through
direct involvement of any of the three major barrier compo-
nents: the intercellular lipid layers, the cornified cell envelop,
and the keratin–filaggrin degradation products. Interestingly,
impaired filaggrin processing has been seen in some animal
models involving altered function of enzymes, such as 12
R-lipoxygenase, that have no obvious roles in degradation
and/or modification of profilaggrin (Epp et al., 2007). Defects
in epidermal differentiation processes even at early stages of
differentiation could affect downstream filaggrin processing.
The defects in filaggrin degradation seen in the keratinocytes
isolated from IFAH patient might, therefore, be an indirect
event associated with the loss of matriptase. The likely indirect
role of matriptase in the formation of SC barrier may also
explain the much milder clinical manifestation of matriptase
deficiency in IFAH patients. This is in stark contrast to what
has been observed in matriptase knockout mice. For these
mice, matriptase has been clearly detected by gene trapping in
suprabasal keratinocytes, with highest expression of matriptase
observed at the outermost viable layer in which the formation
of the SC barrier is actively at work (Netzel-Arnett et al.,
2006). The much more severe defects in skin barrier in
matriptase knockout mice could result from a direct
involvement of mouse matriptase in the late stage of
epidermal differentiation. In spite of the stark contrast in the
distribution of matriptase expression in the normal mouse
versus human skin, matriptase has been reported to be
expressed at high levels in the basal and spinous layers of
mouse skin after exposure to carcinogens (Szabo et al., 2011).
This interesting phenomenon suggests that mouse matriptase
might have a greater role than simply in terminal
differentiation. It is tempting to speculate that mouse
matriptase could also contribute to the proliferation and
early differentiation, as human matriptase does.
Despite the unusually tight functional and regulatory link-
age between matriptase and HAI-1 in keratinocytes, as well as
in other types of epithelial cells, the observation that HAI-1,
but not matriptase, is highly expressed in the granular layer
(SG) of skin implies that there may be a decoupling of
matriptase–HAI-1 activities in the cells of the SG layer. Unlike
matriptase, HAI-1 may have an active role in the terminal
differentiation of keratinocytes in the SG layer, perhaps by
the inhibition of serine proteases other than matriptase.
The intracellular punctate staining of HAI-1 in the granular
keratinocytes suggests that the Kunitz inhibitor might be
incorporated into keratohyalin granules and/or the lamellar
granules during the processes of terminal differentiation in the
granular layer. Therefore, HAI-1 is more likely than matriptase
to be directly involved in the regulation of profilaggrin
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processing in keratohyalin granules, and in lipid matrix
formation in the lamellar granules in human skin.
The differences in the distribution profile of matriptase in
the skin of human versus rodent could explain the physiolo-
gical basis for the differences in clinical phenotype associated
with matriptase loss in the two species. It is, however,
worthwhile considering the different methodologies used for
the detection of matriptase in both species. We have used five
different extensively characterized matriptase- and HAI-1-
specific mAbs (M32, M24, M19, M58, and M69) for the
immunohistochemistry analyses in our current studies and in
our previously reported work (Benaud et al., 2001, 2002;
Hung et al., 2004; Wang et al., 2009; Tseng et al., 2010; Chen
et al., 2010b). The staining patterns observed with our
antibodies clearly indicate that these proteins are localized
at cell–cell junctions, as expected for integral membrane
proteins such as matriptase and HAI-1. The different distribu-
tion profile between total matriptase and activated matriptase
and between total matriptase and HAI-1 would be seen to
exclude the possibility of nonspecific staining by our mAb of
any of the abundant structural proteins found in skin. Our
conclusions regarding the matriptase distribution profile in
human skin was further bolstered by our data generated using
human skin grafted to the back of nude mice and the in vitro
skin equivalents. The former further demonstrates the specifi-
city of our matriptase mAb M32, which does not interact with
mouse matriptase. The latter clearly shows the dynamics of
matriptase expression over the course of differentiation with
the loss of matriptase expression at the late stage of differ-
entiation, consistent with what has been observed in human
skin. Furthermore, matriptase mRNA was clearly detected in
both the basal and spinous layers of human skin by in situ
hybridization in our previous study (Oberst et al., 2003),
consistent with the detection of matriptase protein in both
layers in the current study (Figure 2). With regard to the
assessment of whether matriptase is expressed in the granular
layer of human skin, a tissue section with clear granular layer
is required. In our previous study (Oberst et al., 2003), the
granular layer was not as easy to discern as it is in samples
used in our current study. As a result, the expression of
matriptase in the granular layer could not be clearly
determined and was, we believe, misinterpreted as being
positive owing to the proximity of the strong staining in the
spinous layers. Our current study is also at odds with two
previous studies in which human matriptase protein was
detected by immunohistochemistry in the suprabasal layers
but not in the basal layer of human skin (Bocheva et al., 2009)
and skin raft cultures (Mildner et al., 2006). In both of these
studies, however, matriptase was mainly detected
intracellularly, which is inconsistent with the known integral
membrane protein nature of matriptase.
In ARIH patients, two different matriptase mutations were
identified. One (G827R) is in the serine protease domain
(Basel-Vanagaite et al., 2007), likely resulting in defects in
zymogen activation (Desilets et al., 2008), whereas the other
(M1I) replaces the translation initiator, resulting in the loss of
the intracellular, transmembrane, and a small portion of
extracellular domain (Avrahami et al., 2008). If translated,
the matriptase M1I mutant might become an intracellular
protein. In IFAH patients, a splice-site mutation and a frame-
shift deletion were identified, both resulting in the loss of
matriptase expression. Given the differential distribution and
likely different biology of matriptase in humans versus mice,
the development of human relevant models would be desired
for understanding the disease progression for ARIH and IFAH.
The organotypic skin culture system using human primary
keratinocytes provides a relevant model that faithfully presents
the distribution profile of matriptase expression in normal
human skin. Our high-efficiency MTP KD system can
significantly reduce matriptase expression in HaCaT human
keratinocytes, which has allowed us to probe the role of
matriptase in keratinocyte proliferation and early
differentiation. The HaCaT cell model is consistent with the
distribution profile of matriptase expression observed in the
immunohistochemistry of human skin samples and rafts.
Furthermore, the adaptation of HaCaT cells to a basal cell-
like state through Ca2þ -induced keratinocyte differentiation
allows us to study the potential role of matriptase over the
course of keratinocyte differentiation. In addition to revealing
the role of human matriptase in the proliferation and early
differentiation, both models and their combination would
provide a tool to further understand the etiology of ARIH
and IFAH.
In summary, we have provided several lines of evidence
that lend support to the hypothesis that the primary physiolo-
gical function of matriptase in human skin lies in proliferation
and early differentiation of keratinocytes, rather than terminal
differentiation. Dysregulated matriptase, as observed in ARIH
and IFAH, could affect the functions of basal and spinous
keratinocytes. The divergence between human and mouse
in matriptase distribution and physiological role in the skin
underscores the necessity to develop more human
relevant models for the study of the role of matriptase in skin
diseases.
MATERIALS AND METHODS
Cell lines and cell cultures
Human primary keratinocytes were obtained from neonatal foreskin
and maintained in Keratinocyte-SFM (Invitrogen, Grand Island, NY)
supplemented with bovine pituitary extract (20–30mg ml 1), recom-
binant epidermal growth factor (0.1–0.2 ng ml 1), 100 units ml 1
penicillin, and 100mg ml 1 streptomycin. Human keratinocyte
HaCaT cells were maintained in DMEM (Mediatech, Manassas, VA)
supplemented with 10% heat-inactivated fetal bovine serum (Gemini,
West Sacramento, CA), 100 units ml 1 penicillin, and 100mg ml 1
streptomycin. HaCaT clones of MTP KD and the non-target control,
generated with matriptase shRNA, as previously described (Chen
et al., 2010b), were maintained in DMEM supplemented with 10%
fetal bovine serum, 2mg ml 1 puromycin, 100 units ml 1 penicillin,
and 100mg ml 1 streptomycin. The stably basal-like HaCaT
cells were generated by culturing HaCaT cells in the completed
Keratinocyte-SFM, which contains only 0.03 mM calcium, for at least
1 month, as previously described (Deyrieux and Wilson, 2007;
Micallef et al., 2009). These basal-like HaCaT cells were switched
from low-calcium completed Keratinocyte-SFM to high-calcium
completed DMEM in order to induce differentiation (Deyrieux and
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Wilson, 2007). All cells were incubated in a humidified incubator at
37 1C with 5% CO2.
Antibodies
The total matriptase monoclonal antibodies M24 and M32 and the
activated matriptase mAb M69 were generated using the matriptase–
HAI-1 complex as antigen, as described previously (Lin et al., 1999).
The total matriptase mAbs recognize both latent and activated forms
of matriptase. M69 mAb recognizes an epitope only present on
activated matriptase, and therefore it is able to distinguish activated
matriptase from latent matriptase (Tseng et al., 2010; Chen et al.,
2010b). Human HAI-1 protein was detected using the HAI-1 mAb
zM19.
Immunoblot analysis
Proteins for immunoblot analyses were prepared by dissolving cells in
DPBS containing 1% Triton X-100 and 1 mM (5,50-dithiobis-(2-
nitrobenzoic acid). Insoluble debris was removed by centrifugation,
and the protein concentration was determined using the Bradford
Assay (Sigma-Aldrich, St Louis, MD) according to the manufacturer’s
instructions. Samples containing the same amount of total protein
were diluted with 5X sample buffer in the absence of a reducing agent
and resolved by 7.5% SDS-PAGE, followed by transfer to a nitro-
cellulose membrane (Pall, Pensacola, FL). The membranes were
probed with the desired monoclonal antibodies and an HRP-con-
jugated secondary antibody (Kirkegaard & Perry Laboratories,
Gaithersburg, MD), followed by signal detection with Western Light-
ning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences,
Waltham, MA).
Crystal violet cell proliferation assay
Matriptase knockdown HaCaT cells and the non-target control cells
were seeded in 6-well plates at a density of 104 cells per well. Cells
were fixed for 10 minutes in a solution of 3.7% buffered formalin on
the desired days. The cells were washed with DPBS and subsequently
stained with 0.5% crystal violet dissolved in 20% methanol in DPBS
for 10 minutes. After removing the excess stain and washing the cells
with water, the crystal violet-stained cells were dissolved in 2 ml of a
1% SDS solution by agitating the plates on an orbital shaker until the
color was uniformly distributed in the solution. The optical density of
the extracted dye was read with a spectrophotometer (Bechman,
Fullerton, CA, DTX 880) at 595 nm. Optical density is proportionate
to the number of cells in the well, and values were normalized to the
reading on day 1.
Real-time PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. Briefly, chloroform was
added to homogenized samples followed by centrifugation to isolate
the aqueous layer. After the RNA was precipitated, it was washed
in 70% ethanol three times, air-dried, and dissolved in water. One
microgram of total RNA was treated with DNase and used for
complementary DNA synthesis. The complementary DNA synthesis
step included a control reaction without reverse transcriptase. Real-
time PCR reactions were conducted using SYBR green and the
following gene-specific primers: matriptase forward: 50-ATCGCCTAC
TACTGGTCTGA G-30 and matriptase reverse: 50-GTTTTGGAGTCCG
TGGGGAAA-30; HAI-1 forward: 50-GTC GGGGTGTGCAAGGTGG
G-30 and HAI-1 reverse: 50-GCGGAACTGGGTGGGCTGAC-30; K1
forward: 50-ATTTCTGAGCTGAATCGTGTGATC-30 and K1 reverse: 50-
CTTGGCATCCT TGAGGGCATT-30; K10 forward: 50-TGATGTGAATG
TGGAAATGAATGC-30 and K10 reverse: 50-GTAGTCAGTTCCTTGCT
CTTTTCA-30; involucrin forward: 50-GGGTGGTTATT TATGTTTGGG
TGG-3’ and involucrin reverse: 50-GCCAGGTCCAAGACATTCAA
C-30; glyceraldehyde-3-phosphate dehydrogenase forward 50-TGCA
CCACCAACTGCTTAGC-30 and glyceraldehyde-3-phosphate dehy-
drogenase reverse 50-GGCATGGA CTGTGGTCATGAG-30. All reac-
tions were normalized to glyceraldehyde-3-phosphate dehydrogenase
as an internal control. The RT-PCR reaction conditions were as
follows: initiation for 2 minutes at 50 1C and then for 10 minutes at
95 1C, followed by 45 cycles of switching between 95 1C for
15 seconds and 60 1C for 1 minute.
Immunohistochemistry
Immunohistochemical staining was performed as previously
described (Chen et al., 2010a, 2011). Tissue sections of paraffin-
embedded human skin, skin equivalents, human skin xenograft,
frozen sections of human skin, and paraffin-embedded human skin
xenograft were stained using the total matriptase mAb M24 or M32,
activated matriptase mAb M69, and HAI-1 mAb M19. Frozen human
skin tissue sections were obtained from Tri-Service General Hospital,
National Defense Medical Center under the IRB 099-05-019,
approved by TSGHIRB. The human skin xenograft was obtained
from a human–mouse xenograft model, which is generated by
engrafting normal human skin harvested from elective abdomino-
plasty resections onto athymic nude (nu/nu) mice (Harlan Labora-
tories, Frederick, MD). The specimens stained here were harvested
140 days after engraftment. This study was approved by the George-
town University Medical Center Animal Care and Use Committee
(GUACUC# 2011-050). The use of unidentified tissue is not con-
sidered human subjects’ research, and therefore this research did not
require prospective review of approval by the Georgetown University
Medical Center Institutional Review Board. DAB (3,30-Diaminoben-
zidine) and the secondary antibody (EnVisionþ Dual Link System
Peroxidase) (Dako, Glostrup, Denmark) were used for the detection of
positive staining. Cell nuclei were counterstained with hematoxylin.
Images were captured using an Olympus AH2 Vanox Microscope
System (Olympus, Melville, NY).
Organotypic culture
Organotypic rafts were generated based on the protocol described
previously with minor revision (Stark et al., 1999, 2004; Chen et al.,
2010b). Briefly, type I collagen (BD Biosciences, Bedford, MA) plugs
with 7.5 104 human primary fibroblasts per plug were prepared in
6-well cell culture inserts (BD Biosciences) and incubated for 2–5
days. A total of 106 primary keratinocytes were applied to the center
of each collagen plug and incubated for 1–4 days. Differentiation of
the rafts was initiated by lifting them to the air–liquid interface.
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